Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...

AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.

Collaboration leverages AbbVie's expertise in oncology and immunology ... "At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome," said ...